文献速递胸部腹部介入CT

经皮CT引导下肾上腺病变活检在已知或疑似肺癌患者中的作用

The role of percutaneous CT-guided biopsy of an adrenal lesion in patients with known or suspected lung cancer.
PubMed 文献 · Abdom Radiol (NY) · 2020-09-18

本回顾性研究分析了1993年4月至2019年5月间343例已知或疑似肺癌患者的357次经皮肾上腺活检,评估其对肺癌转移的诊断效能及并发症。结果显示活检对肺癌转移的敏感度97%、特异度100%,非诊断率0.6%,轻微并发症发生率1.1%,无严重并发症;超过20%的肾上腺病变与肺癌无关。

要点

  • 对肺癌转移的敏感度97%、特异度100%,非诊断率0.6%。
  • 超过20%的肾上腺病变并非肺癌转移,活检可明确性质。
  • 轻微并发症发生率1.1%,无严重并发症,操作安全。

核心结论

  • 在已知或疑似肺癌患者中,超过20%的肾上腺病变与肺癌无关。
  • 经皮肾上腺活检对肺癌转移具有高敏感度和特异度,且操作安全。

研究设计与样本

  • 回顾性分析,经机构审查委员会批准并豁免知情同意。
  • 纳入1993年4月至2019年5月间343例已知或疑似肺癌患者(男164例、女179例,平均年龄66岁)的357次经皮肾上腺活检。
  • 最终诊断依据病理(活检和/或手术切除)或活检后CT影像随访至少12个月;随访不足12个月者排除(n=44)。

诊断标准与关键数值

  • 活检对肺癌转移的敏感度97%、特异度100%。
  • 非诊断率为0.6%。
  • 最终诊断:肺癌转移235例(77.8%),肺外原发转移2例(0.7%),嗜铬细胞瘤2例(0.7%),良性病变63例(20.9%)。

临床应用与阅片要点

  • 对已知或疑似肺癌患者的肾上腺病变行经皮活检,可明确病变是否为肺癌转移。
  • 病变较大者更可能为恶性(p=0.0000)且更易正确分类为肺癌转移(p=0.025)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To determine the sensitivity, specificity, and complication rate of percutaneous adrenal biopsy in patients with known or suspected lung cancer.

METHODS: This study was approved by the Institutional Review Board at our institution as a retrospective analysis; therefore, the need for informed consent was waived. All percutaneous adrenal biopsies performed between April 1993 and May 2019 were reviewed. 357 of 582 biopsies were performed on 343 patients with known or suspected lung cancer (M:F 164:179; mean age 66 years). The biopsy results were classified into malignant, benign, or non-diagnostic. The final diagnosis was established by pathology (biopsy and/or surgical resection) or imaging follow-up on CT for at least 12 months following the biopsy. Patients with less than 12 months follow-up were excluded (n = 44). Complications were recorded.

RESULTS: The final diagnosis was metastatic lung cancer in 235 cases (77.8%), metastasis from an extrapulmonary primary in 2 cases (0.7%), pheochromocytoma in 2 cases (0.7%), and benign lesions in 63 cases (20.9%). Percutaneous adrenal gland biopsy had a sensitivity of 97% and specificity of 100% for lung cancer metastases. The non-diagnostic rate was 0.6%. Larger lesions were more likely to be malignant (p = 0.0000) and to be correctly classified as a lung metastasis (p = 0.025). The incidence of minor complications was 1.1%. There were no major complications.

CONCLUSION: Over 20% of adrenal lesions in patients with known or suspected lung cancer were not related to lung cancer. Percutaneous adrenal gland biopsy is a safe procedure, with high sensitivity and specificity for lung cancer metastases.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. McDermott E, Kilcoyne A, O'Shea A, et al. The role of percutaneous CT-guided biopsy of an adrenal lesion in patients with known or suspected lung cancer. Abdom Radiol (NY). 2020. PMID: 32945923. doi:10.1007/s00261-020-02743-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。